miR‑489‑3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2

Sun,Dan; Li,Tianren; Xin,Haotian; An,Jun; Yang,Jieping; Lin,Jiaxing; Meng,Xin; Wang,Biao; Ozaki,Toshinori; Yu,Meng; Zhu,Yuyan

doi:10.3892/ol.2020.11869

miR‑489‑3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2

Authors:
- Dan Sun
- Tianren Li
- Haotian Xin
- Jun An
- Jieping Yang
- Jiaxing Lin
- Xin Meng
- Biao Wang
- Toshinori Ozaki
- Meng Yu
- Yuyan Zhu
View Affiliations

Affiliations: Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Biochemistry and Molecular Biology, School of Life Sciences, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of DNA Damage Signaling, Research Center, The 5th Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Key Laboratory of Transgenetic Animal Research, Department of Laboratory Animal Science, China Medical University, Shenyang, Liaoning 110122, P.R. China
Published online on: July 15, 2020 https://doi.org/10.3892/ol.2020.11869
Article Number: 8
Copyright : © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since human bladder cancer (BC) is a common malignancy of the urinary system with poor prognosis, it is crucial to clarify the molecular mechanisms of BC development and progression. To the best of our knowledge, the current study demonstrated for the first time that miR‑489‑3p suppressed BC cell‑derived tumor growth in vivo via the downregulation of histone deacetylase 2 (HDAC2). According to the results, expression levels of miR‑489‑3p were lower in BC tissues compared with corresponding normal tissues. Expression of miR‑489‑3p mimics in BC‑derived T24 and 5637 cells resulted in a significant reduction in proliferation and migration rates. Furthermore, bioinformatics analyses indicated that HDAC2 may be a potential downstream target of miR‑489‑3p. In contrast to miR‑489‑3p, HDAC2 was expressed at higher levels in BC tissues compared with corresponding normal tissues. Additionally, small interfering RNA‑mediated knockdown of HDAC2 caused a marked decrease in the proliferation and migration rates of T24 and 5637 cells. Consistent with these observations, expression of miR‑489‑3p mimics attenuated the growth of xenograft tumors arising from T24 cells and resulted in HDAC2 downregulation. In conclusion, the results of the current study indicated that the miR‑489‑3p/HDAC2 axis serves a role in the development and/or the progression of BC and may be a potential molecular target for the development of a novel strategy to treat patients with BC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Enokida H, Yoshino H, Matsushita R and Nakagawa M: The role of microRNAs in bladder cancer. Investig Clin Urol. 57 (Suppl 1):S60–S76. 2016. View Article : Google Scholar : PubMed/NCBI
3	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
4	Rose TL and Milowsky MI: Improving systemic chemotherapy for bladder cancer. Curr Oncol Rep. 18:272016. View Article : Google Scholar : PubMed/NCBI
5	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
6	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
7	Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 8:93–103. 2007. View Article : Google Scholar : PubMed/NCBI
8	Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky AM, et al: miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget. 1:710–720. 2010. View Article : Google Scholar : PubMed/NCBI
9	Malizia AP and Wang DZ: MicroRNAs in cardiomyocyte development. Wiley Interdiscip Rev Syst Biol Med. 3:183–190. 2011. View Article : Google Scholar : PubMed/NCBI
10	Taft RJ, Pang KC, Mercer TR, Dinger M and Mattick JS: Non-coding RNAs: Regulators of disease. J Pathol. 220:126–139. 2010. View Article : Google Scholar : PubMed/NCBI
11	van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 17:212015. View Article : Google Scholar : PubMed/NCBI
12	Cheng L, Yang T, Kuang Y, Kong B, Yu S, Shu H, Zhou H and Gu J: MicroRNA-23a promotes neuroblastoma cell metastasis by targeting CDH1. Oncol Lett. 7:839–845. 2014. View Article : Google Scholar : PubMed/NCBI
13	Pan Y, Li J, Zhang Y, Wang N, Liang H, Liu Y, Zhang CY, Zen K and Gu H: Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Sci Rep. 6:257982016. View Article : Google Scholar : PubMed/NCBI
14	Liang Z, Li X, Liu S, Li C, Wang X and Xing J: MiR-141-3p inhibits cell proliferation, migration and invasion by targeting TRAF5 in colorectal cancer. Biochem Biophys Res Commun. 514:699–705. 2019. View Article : Google Scholar : PubMed/NCBI
15	Schoolmeesters A, Eklund T, Leake D, Vermeulen A, Smith Q, Force Aldred S and Fedorov Y: Functional profiling reveals critical role for miRNA in differentiation of human mesenchymal stem cells. PLoS One. 4:e56052009. View Article : Google Scholar : PubMed/NCBI
16	Cheung TH, Quach NL, Charville GW, Liu L, Park L, Edalati A, Yoo B, Hoang P and Rando TA: Maintenance of muscle stem-cell quiescence by microRNA-489. Nature. 482:524–528. 2012. View Article : Google Scholar : PubMed/NCBI
17	Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T and Luo Y: MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet. 205:113–123. 2012. View Article : Google Scholar : PubMed/NCBI
18	Mayr C, Hemann MT and Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 315:1576–1579. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zhang B, Ji S, Ma F, Ma Q, Lu X and Chen X: miR-489 acts as a tumor suppressor in human gastric cancer by targeting PROX1. Am J Cancer Res. 6:2021–2030. 2016.PubMed/NCBI
20	Yuan P, He XH, Rong YF, Cao J, Li Y, Hu YP, Liu Y, Li D, Lou W and Liu MF: KRAS/NF-κB/YY1/miR-489 signaling axis controls pancreatic cancer metastasis. Cancer Res. 77:100–111. 2017. View Article : Google Scholar : PubMed/NCBI
21	Gao S, Liu H, Hou S, Wu L, Yang Z, Shen J, Zhou L, Zheng SS and Jiang B: miR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer. Clin Transl Oncol. 20:703–712. 2018. View Article : Google Scholar : PubMed/NCBI
22	Cui X, Kong C, Zhu Y, Zeng Y, Zhang Z, Liu X, Zhan B, Piao C and Jiang Z: miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing cylindromatosis expression. Oncotarget. 7:48547–48561. 2016. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 467:596–599. 2010. View Article : Google Scholar : PubMed/NCBI
25	Li J, Qu W, Jiang Y, Sun Y, Cheng Y, Zou T and Du S: miR-489 suppresses proliferation and invasion of human bladder cancer cells. Oncol Res. 24:391–398. 2016. View Article : Google Scholar : PubMed/NCBI
26	Soni M, Patel Y, Markoutsa E, Jie C, Liu S, Xu P and Chen H: Autophagy, cell viability, and chemoresistance are regulated by miR-489 in breast cancer. Mol Cancer Res. 16:1348–1360. 2018. View Article : Google Scholar : PubMed/NCBI
27	Wu H, Xiao Z, Zhang H, Wang K, Liu W and Hao Q: MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anticancer Drugs. 25:799–809. 2014. View Article : Google Scholar : PubMed/NCBI
28	Xie Z, Cai L, Li R, Zheng J, Wu H, Yang X, Li H and Wang Z: Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12. Tumour Biol. 36:6497–6505. 2015. View Article : Google Scholar : PubMed/NCBI
29	Liu Q, Yang G and Qian Y: Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway. Mol Carcinog. 56:1312–1321. 2017. View Article : Google Scholar : PubMed/NCBI
30	Thurn KT, Thomas S, Raha P, Qureshi I and Munster PN: Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 12:2078–2087. 2013. View Article : Google Scholar : PubMed/NCBI
31	Tang W, Zhou W, Xiang L, Wu X, Zhang P, Wang J, Liu G, Zhang W, Peng Y, Huang X, et al: The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer. Nat Commun. 10:6632019. View Article : Google Scholar : PubMed/NCBI
32	Li S, Wang F, Qu Y, Chen X, Gao M, Yang J, Zhang D, Zhang N, Li W and Liu H: HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells. Oncol Lett. 13:403–409. 2017. View Article : Google Scholar : PubMed/NCBI
33	Krämer OH: HDAC2: A critical factor in health and disease. Trends Pharmacol Sci. 30:647–655. 2009. View Article : Google Scholar : PubMed/NCBI
34	Shi TP, Xu H, Wei JF, Ai X, Ma X, Wang BJ, Ju ZH, Zhang GX, Wang C, Wu ZQ and Zhang X: Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. J Urol. 180:361–366. 2008. View Article : Google Scholar : PubMed/NCBI
35	Orenay-Boyacioglu S, Kasap E, Gerceker E, Yuceyar H, Demirci U, Bilgic F and Korkmaz M: Expression profiles of histone modification genes in gastric cancer progression. Mol Biol Rep. 45:2275–2282. 2018. View Article : Google Scholar : PubMed/NCBI
36	Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH and Nam JH: Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol. 19:185–190. 2008. View Article : Google Scholar : PubMed/NCBI
37	Shan W, Jiang Y, Yu H, Huang Q, Liu L, Guo X, Li L, Mi Q, Zhang K and Yang Z: HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. Am J Cancer Res. 7:1213–1226. 2017.PubMed/NCBI
38	Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P and Schulz WA: Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol. 31:1770–1779. 2013. View Article : Google Scholar : PubMed/NCBI
39	Pinkerneil M, Hoffmann MJ, Deenen R, Köhrer K, Arent T, Schulz WA and Niegisch G: Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol Cancer Ther. 15:299–312. 2016. View Article : Google Scholar : PubMed/NCBI
40	La Noce M, Paino F, Mele L, Papaccio G, Regad T, Lombardi A, Papaccio F, Desiderio V and Tirino V: HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: A study on a putative new target for CSCs directed therapy. J Exp Clin Cancer Res. 37:2962018. View Article : Google Scholar : PubMed/NCBI
41	Sun D, Yu M, Li Y, Xing H, Gao Y, Huang Z, Hao W, Lu K, Kong C, Shimozato O, et al: Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway. FEBS Open Bio. 9:478–489. 2019. View Article : Google Scholar : PubMed/NCBI